SEP 14 7005 BE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW

Amnon PELED et al

; Serial No.:

10/649,873

, Filed:

August 28, 2003

For:

NOVEL CHEMOKINE BINDING PEPTIDES CAPABLE

OF MODULATING THE BIOLOGICAL ACTIVITY OF

CHEMOKINES

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1632

Attorney

\$ \$\text{\$\}\$}}}}\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\exititt{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\

Docket: 26732

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Nartin O. Maynihan

Martin Moynihan

Registration No. 40,338

Dated: August 28, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the	DOINGIK	Reduction Act of 1993, no persons	are required t	o respond to a ce	meetion of information unless it contains a	a vanu Or	VIB CONGOI HUMOCI.		
RIPA		Substitute for form 1449A/I	DTO.		Complete if Known				
_			· ·		Application Number	10/6	10/649,873		
1		RMATION DISC			Filing Date	Aug	August 28, 2003		
,	STAT	TEMENT BY APP	LICA	NT.	First Named Inventor	PEL	PELED Amnon et al		
	(ı	ise as many sheets as nec	essary)		Art Unit	1632	632		
_					Examiner Name				
Sheet			of		Attorney Docket Number	2673	2		
			U.S.	PATENT	DOCUMENTS				
Examiner Initials*	Cite No. 1 Document Number		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number-Kind Code ^{2 (if known)}							
	1	US-2004/0171552	02-2-2004		Peled et al.				
	<u> </u>								
				_					
	<u> </u>								
I	I	I	l						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T			
	2	PCT WO 03/072599	04-4-2003	Peled et al.		П			
	3	PCT WO 02/061087	08-8-2002	Burmer et al.					
Examine Signatur				Date Considered		Ħ			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/649,873 Filing Date August 28, 2003 INFORMATION DISCLOSURE First Named Inventor PELED Amnon et al STATEMENT BY APPLICANT Group Art Unit 26732 **Examiner Name** (use as many sheets as necessary) Sheet Attorney Docket Number OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T² **Initials** No.1 publisher, city and/or country where published. 4 Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ ID No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Abstract. 5 Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combat Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. 6 Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Binding to and Activating Human Blood Neutrophils 1", The Journal of Immunology, 154: 814-824, 1995. 7 Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate From the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 in CCR5 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Virology, 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing HIV-1/AIDS Infection and Progression", The American Society for Biochemistry and Molecular Biology, P.1-38, 2003.

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.